Heath #AACR19 Analogy: 4 time-frozen snapshots of cars; never see the same car, but figure out trajectory of cars p… https://t.co/iubIug4ptb
7:15am April 2nd 2019 via Twitter Web Client
Heath #AACR19 Get ave protein/metabolite, dispersion, and correlations between analytes. All done single-cell level… https://t.co/lr865btMqQ
7:13am April 2nd 2019 via Twitter Web Client
Heath #AACR19 From metabolic enzymes, metabolic regulators, sensitive state marker, resistant state marker, signaling transducer.
7:12am April 2nd 2019 via Twitter Web Client
Heath #AACR19 By day 3 of BRAFinh: chr is remodeled via atac-seq data. Chr6 NP1, Chr22. Can do targeted metabolomics. Shows metabolites
Heath #AACR19 Cell state changes: BRAFinh of pt-derived M397 triggers rapid cell-state dedifferentiation. Plastic t… https://t.co/vWCiQ4d0ub
7:10am April 2nd 2019 via Twitter Web Client
Heath #AACR19 Shows hetergeneous mix of cell compositions; shows images of one cell, any phenotype: regenerate tumor.
7:08am April 2nd 2019 via Twitter Web Client
Heath #AACR19 2 topics: adaptive resistance in melanoma, investigation into MHC
7:05am April 2nd 2019 via Twitter Web Client
James Heath (Caltech CA) #AACR19 New Single-Cell Methods for Oncology and Immuno-oncology
Post Edited: Miltenyi MACSima Imaging and Arima Genomics debut at the American Association for Cancer Research 2019… https://t.co/tR6WyPupra
6:17am April 2nd 2019 via WP to TWTR on Yuzuki.org
New post: Miltenyi MACSima Imaging and Arima Genomics debut at the American Association for Cancer Research 2019… https://t.co/xLFJuUWp3D
5:57am April 2nd 2019 via WP to TWTR on Yuzuki.org
OHSU’s Gordon Mills and @Nanostring CSO Joe Beechem talking about some recent GeoMx history #AACR19 “Will this go t… https://t.co/vaBt5SdPz0
8:00pm April 1st 2019 via Twitter for iPhone
@nanostring CSO Ioe Beechem: “From concept to finished instrument in only five years.” A remarkable feat for anyone… https://t.co/Fh4dajaa1l
7:57pm April 1st 2019 via Twitter for iPhone
@nanostringtech CEO Brad Gray at #AACR19 GeoMx launch: “I’ve waited three years for this moment”. Awesome intro vid… https://t.co/gSZBDUisZR
7:51pm April 1st 2019 via Twitter for iPhone
ICYMI RT @DaleYuzuki: Hi #AACR19 New Post: Akoya Biosciences and Berkeley Lights debut at American Association for… https://t.co/E1fdHHlT1H
4:15pm April 1st 2019 via Hootsuite Inc.
Braggio #AACR19 Conclude: very promising, all bulk seq vars were detected, very good correlation in VAF.
3:53pm April 1st 2019 via Twitter Web Client
Braggio #AACR19 Able to reconstruct tumor phylogeny in MBL to CLL progression. Showed scVAF compared to bulk VAF measured down to 1%.
3:51pm April 1st 2019 via Twitter Web Client
De Bono #AACR19 Reads/cell for 5 samples, both HiSeq and NovaSeq range from 10K to 37K/cell. About 150M reads per c… https://t.co/cHlnLNb0u9
3:48pm April 1st 2019 via Twitter Web Client
Braggio #AACR19 TP53 have unfavorable prognostic impact in CLL irrespective of (sub)clonal status.
3:44pm April 1st 2019 via Twitter Web Client
Braggio #AACR19 1-2% of pre-leukemic will become asymptomatic CLL every year. Watch and wait: another area where es… https://t.co/xztbqDwF7K
3:39pm April 1st 2019 via Twitter Web Client
Braggio #AACR19 Early results from n=5 so far of 500 patients. CLL - from pre-malignant to asymptomatic, to progres… https://t.co/0lpZOUIcF2
3:38pm April 1st 2019 via Twitter Web Client
Esteban Braggio (Mayo Clinic AZ) Single-Cell genomics studies in MBL and CLL
3:36pm April 1st 2019 via Twitter Web Client
Q: How to tell the 3% selected vs 97% unselected? Takahashi #AACR19 Did replicate sampling and found identical data.
3:35pm April 1st 2019 via Twitter Web Client
Q: What is the difference to MDA (WGA)? Method of phylogen tree? Takahashi: #AACR19 Targeted sc amplicon, error rat… https://t.co/oOloLobvqQ
3:33pm April 1st 2019 via Twitter Web Client
Takahashi #AACR19 Concl - not inferring clonal architecture, they can show it directly. Also lessons in technical l… https://t.co/tFOzBT5THq
3:31pm April 1st 2019 via Twitter Web Client
Takahashi #AACR19 74yo male, t-AML, BM blast 62%; treated w/azacitidine, sorefenib, remission. 9 mo relapse BM blas… https://t.co/XfklaoNTmC
3:29pm April 1st 2019 via Twitter Web Client
Takahashi #AACR19 Both divergent and convergent evolution demonstrated. Longitudinal samples - 20 cases. Shows tumo… https://t.co/bG23C8GPPF
3:28pm April 1st 2019 via Twitter Web Client
Takahashi #AACR19 Reconstructing phylogeny in AML, different branches https://t.co/w8TUnmr0Dk
3:27pm April 1st 2019 via Twitter for iPhone
Takahashi #AACR19 Same exclusions of IDH1/2; also FLT3-ITD and FLIT3-TKD.
3:25pm April 1st 2019 via Twitter Web Client
Takahashi #AACR19 showing mutually exclusive muts: KRAS and NRAS do not co-occur. w/8K cells, statistically sig via Fisher's exact.
3:24pm April 1st 2019 via Twitter Web Client
Takahashi #AACR19 low-coverage solved by NextSeq, HiSeq w/higher coverage. Analysis of MAF LoD: Mission says 0.1%;… https://t.co/v5GmQ3OhAt
3:23pm April 1st 2019 via Twitter Web Client
Takahashi #AACR19 270K cells put in, only 3% get sequenced (7617 cels). Allele drop-out rate est. from SNP loci 8.7… https://t.co/4PbZui5Mgw
3:21pm April 1st 2019 via Twitter Web Client
Takahashi #AACR19 70 AML pts, 40 amplicons w/19 AML genes. Bulk NGS: >100% of muts were validated; SNP array confirmed zygosity.
3:20pm April 1st 2019 via Twitter Web Client
Takahashi #AACR19 From VAF alone of different mutations, you'll need longitudinal samples. Navin '11, Pellegrino '18 https://t.co/SmPnzbqt2R
3:18pm April 1st 2019 via Twitter Web Client
Takahashi #AACR19 More data today at 4pm in A-302 as well. Clonal heterogeneity - not linear, it is branched. '12 https://t.co/xROwr1SBXc
3:15pm April 1st 2019 via Twitter Web Client
Koichi Takahashi (MD Anderson) #AACR19 Unraveling clonal hetergeneity and evolutionary history of AML by sc DNA sequencing
3:13pm April 1st 2019 via Twitter Web Client
#AACR19 Beard: 500 samples x 5K cells = 2.5M datapoints. Have iterative QC data they get feedback on performance. T… https://t.co/1A7IMwGySr
3:12pm April 1st 2019 via Twitter Web Client
#AACR19 Beard: Amplicon design to 20k genes; platforms supported: MiSeq, HiSeq, NextSeq, NovaSeq. On-demand cloud tool.
3:08pm April 1st 2019 via Twitter Web Client
#AACR19 Beard: New chem is fast (faster TAT on custom), efficient (better uniformity), targeted w/higher plexy - from 300-500 now to 1000.
3:07pm April 1st 2019 via Twitter Web Client
#AACR19 Beard: Tapestri "the only targeted single-cell analysis platform'. Cell into droplets, joins to barcoded beads and reagents.
3:06pm April 1st 2019 via Twitter Web Client
#AACR19 @missionbio Nigel Beard, VP of R&D. 1/3 of us will experience cancer; 9B: est. population of the world in 2… https://t.co/nfKP3b
3:05pm April 1st 2019 via Twitter Web Client
De Bono #AACR19 CTC-STOP one publication https://t.co/1OA27UUO8u When possible: embed circ biomarkers into Ph I/II… https://t.co/CGUN5kN5tl
7:44am April 1st 2019 via Twitter Web Client
Hi #AACR19 New Post: Akoya Biosciences and Berkeley Lights debut at American Association for Cancer Research 2019… https://t.co/X9y240JdEc
7:43am April 1st 2019 via WP to TWTR on Yuzuki.org
De Bono #AACR19 Can avoid over-Rx. CTC-STOP trial: based only on CTC counts. Need to show clinical utility. https://t.co/149t9MrIl1
7:42am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Looked at 10-15 CTCs per pt. Benefit to pt: can transform clinical pt care: freq testing feasible,… https://t.co/LI7gWbSDl7
7:40am April 1st 2019 via Twitter Web Client
De Bono #AACR19 From 200 CTCs: copy number data from 200 scCTCs cp with mCRPC exomes very similar. Shows sig intra-pt heterogeneity.
7:38am April 1st 2019 via Twitter Web Client
De Bono #AACR19 In cancer pts: n>50, tolerated well. '18 CCR https://t.co/3ijvDKjxbb Shows increase of yield in PrCa. 1000x yield.
7:36am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Major limitation: low cell count. Diagnostic apheresis: mean of >10K CTCs in 50mL apheresis product… https://t.co/kq1aXkU
7:35am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Serial single CTC low-pass WGS: manuscript in prep. Neves AACR 2018: changes of subclones over time… https://t.co/CtAvA5hj8F
7:34am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Before Rx, Wk 4, Wk 14: 8q gain (MYC) lost by week 4. Pt did not respond, but the Rx did affect the… https://t.co/VoOJ7s79TT
7:33am April 1st 2019 via Twitter Web Client
De Bono #AACR19 TOPARP-A, TO-PARP-B will be ASCO2019. Single CTC isolation and genomic analysis: subclonal changes during PARPi Rx
7:32am April 1st 2019 via Twitter Web Client
